Moderna Announces Transition to a Clinical Stage Company, Provides Business Updates and Outlines 2016 Strategic Priorities

Moderna Announces Transition to a Clinical Stage Company, Provides Business Updates and Outlines 2016 Strategic Priorities

January 11, 2016

CAMBRIDGE, Mass., January 11, 2016 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, today announced it is now a clinical stage company with its first Phase I study for mRNA 1440 currently underway in Europe. Moderna also announced it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for mRNA 1851, its second clinical program, with a Phase I study anticipated to begin in Q1 2016. mRNA 1440 and mRNA 1851 are infectious disease vaccines for undisclosed targets and indications.

Moderna Therapeutics Teams with Gates Foundation to Advance mRNA-Based Antibody Combination to Help Prevent HIV Infection

Moderna Therapeutics Teams with Gates Foundation to Advance mRNA-Based Antibody Combination to Help Prevent HIV Infection

January 12, 2016

CAMBRIDGE, Mass., January 12, 2016 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, today announced a partnership with the Bill & Melinda Gates Foundation to advance the development of a novel, affordable combination of mRNA-based antibody therapeutics to help prevent human immunodeficiency virus (HIV) infection. The development efforts will be led by Valera, Moderna’s infectious disease-focused venture.

Evelo Therapeutics Establishes Core Executive Team

Evelo Therapeutics Establishes Core Executive Team

January 11, 2016

Cambridge, Mass., January 11, 2016/PRNewswire/ - Evelo Therapeutics, a biotechnology company pioneering the development of microbiome-based therapies for cancer, today announced that it has established its core executive team with the appointment of Mark Bodmer, Ph.D., as chief scientific officer and president of research and development; Kareem Reda as vice president and director of business development and strategy; and William DeVaul as vice president of intellectual property.

Agios Outlines Key 2016 Goals and Priorities

Agios Outlines Key 2016 Goals and Priorities

January 11, 2016

SAN FRANCISCO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today outlined the company’s 2016 strategy and expected clinical development and research milestones in conjunction with the 34th Annual J.P. Morgan Healthcare Conference in San Francisco.

Moderna Therapeutics and PPD Announce Strategic Collaboration to Support Clinical Development of Novel mRNA Therapeutics

Moderna Therapeutics and PPD Announce Strategic Collaboration to Support Clinical Development of Novel mRNA Therapeutics

January 8, 2016

CAMBRIDGE, Mass. and Wilmington, N.C., January 8, 2016 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, and Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), today announced a strategic collaboration to support Moderna’s evolution as a clinical-stage company. Covering a broad expanse of drug modalities and therapeutic areas, Moderna’s pipeline has the potential to address the unmet needs of numerous patients worldwide.

AstraZeneca and Moderna Therapeutics Announce New Collaboration to Co-Develop and Co-Commercialize Immuno-Oncology mRNA Therapeutics™

AstraZeneca and Moderna Therapeutics Announce New Collaboration to Co-Develop and Co-Commercialize Immuno-Oncology mRNA Therapeutics™

January 11, 2016

CAMBRIDGE, Mass., and LONDON, UK, January 11, 2016 — AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics today announced a new collaboration to discover, co-develop and co-commercialize messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers. The collaboration is in addition to the agreement announced by the companies in 2013 to develop mRNA Therapeutics™ for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology.

Moderna Licenses New Vaccine Candidates Against a New Viral Target to Merck

Moderna Licenses New Vaccine Candidates Against a New Viral Target to Merck

January 11, 2016

CAMBRIDGE, Mass., January 11, 2016 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, today announced that Merck, known as MSD outside the United States and Canada, has licensed a vaccine program against an undisclosed viral target, including mRNA 1566 and a set of related novel vaccine candidates, as part of the ongoing collaboration between the companies to discover and develop vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA).

Seres Therapeutics Announces Strategic Collaboration with Nestlé Health Science

Seres Therapeutics Announces Strategic Collaboration with Nestlé Health Science

January 11, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, announced today that it has entered into an agreement with Nestlé Health Science for the development and commercialization outside of the United States and Canada for its product candidates in development for Clostridium Difficile infection (CDI) and inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease.

BIND Therapeutics Presents Complete Data on Clinical Activity of BIND-014 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) at the 2016 Genitourinary Cancers Symposium

BIND Therapeutics Presents Complete Data on Clinical Activity of BIND-014 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) at the 2016 Genitourinary Cancers Symposium

January 7, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today announced the presentation of complete data from its phase 2 clinical trial of BIND-014, a PSMA-targeted ACCURIN containing docetaxel, in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) who either were or were not exposed to anti-androgens (abiraterone acetate and/or enzalutamide).

Seres Therapeutics Announces Appointment of Wael Hashad as Chief Commercial Officer

Seres Therapeutics Announces Appointment of Wael Hashad as Chief Commercial Officer

January 6, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2016-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has appointed Wael Hashad as Chief Commercial Officer and Executive Vice President.